Pharmidex are proud to be part of the recent publication on African Trypanosomiasis in Journal of Antimicrobial Agents
July 19, 2017

Pharmidex team are proud to present it's latest involvement on the recent publication on African Typanosomiasis

Pharmidex are proud to be part of the recent publication on African Trypanosomiasis in Journal of Antimicrobial Agents

Pharmidex are proud to be part of the recent publication on African Trypanosomiasis in Journal of Antimicrobial Agents


The Pharmidex team are proud to present it's latest involvement on the recent publication on African Typanosomiasis which was published in the International journal of antimicrobial agents. Dose-dependent effect and pharmacokinetics of fexinidazole and its metabolites in a mouse model of human African trypanosomiasis - International Journal of Antimicrobial Agents Human African trypanosomiasis (HAT) is a neglected tropical disease, with a population of 70 million at risk. Current treatment options are limited.


In the search for new therapeutics, the repurposing of the broad-spectrum antiprotozoal drug fexinidazole has completed Phase III trials with the anticipation that it will be the first oral treatment for HAT.


For more information please see - https://www.sciencedirect.com/journal/international-journal-of-antimicrobial-agents

June 16, 2026
This well-deserved appointment marks an important milestone in a remarkable career spanning more than 22 years at Pharmidex . Over the years, Dr Chishty has made a significant contribution to the growth of our DMPK capabilities, applying his extensive expertise in Drug Metabolism and Pharmacokinetics to support successful drug discovery and development programmes for clients worldwide. His scientific leadership, dedication and commitment to excellence have been instrumental in strengthening our services and supporting the continued success of Pharmidex . As we continue to grow and support innovative biopharmaceutical companies, we look forward to the impact Dr Chishty will make in this new role. Please join us in congratulating Dr Mansoor Chishty on this achievement and wishing him every success as Director of DMPK.
June 12, 2026
At Pharmidex , we know that great teams are built through collaboration, resilience and shared experiences. Our recent football event brought colleagues together to promote wellbeing, encourage physical activity and strengthen the relationships that help us succeed both on the pitch and in the laboratory. The qualities that drive success in sport, teamwork, dedication and determination are the same values that underpin scientific excellence every day at Pharmidex . As the world looks ahead to the excitement of World Football 2026, we're proud to celebrate the positive impact sport has in bringing people together, inspiring healthy lifestyles, and creating stronger communities. 🔬 Advancing science 🤝 Building stronger teams 💪 Promoting wellbeing ⚽ Celebrating our passion for sport And while football fans may be singing "It's coming home"... at Pharmidex we're convinced that "It's coming lab!" 🧪⚽ From the pitch to the lab, we're proud to champion teamwork, innovation, and a shared passion for achieving great results.
June 8, 2026
Pharmidex is seeking an experienced and driven Principal / Senior Translational Pharmacologist to join our growing Translational Research team and lead innovative ophthalmology programmes. We're looking for a senior scientist with expertise in ophthalmology, ocular disease models, and translational pharmacology who is ready to make a real impact in a dynamic CRO environment. ✅ Competitive salary and benefits ✅ High-visibility scientific leadership role ✅ Opportunities to present at international conferences ✅ Direct impact on advancing innovative medicines toward the clinic
More Posts